{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T01:58:00Z","timestamp":1772071080261,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T00:00:00Z","timestamp":1421193600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1038\/ja.2014.164","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T07:15:16Z","timestamp":1421219716000},"page":"395-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["In vitro evaluation of ciclopirox as an adjuvant for polymyxin B against gram-negative bacteria"],"prefix":"10.1038","volume":"68","author":[{"given":"Kwang-sun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Gu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,14]]},"reference":[{"key":"BFja2014164_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1086\/429323","volume":"40","author":"ME Falagas","year":"2005","unstructured":"Falagas, M. E. & Kasiakou, S. K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40, 1333\u20131341 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2014164_CR2","first-page":"693","volume":"37","author":"S Nakajima","year":"1965","unstructured":"Nakajima, S. Clinical use of colimycin F otic solution. Jibiinkoka 37, 693\u2013697 (1965).","journal-title":"Jibiinkoka"},{"key":"BFja2014164_CR3","first-page":"585","volume":"37","author":"R Ohzawa","year":"1965","unstructured":"Ohzawa, R. The use of colimycin ear drops. Jibiinkoka 37, 585\u2013590 (1965).","journal-title":"Jibiinkoka"},{"key":"BFja2014164_CR4","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1128\/AAC.00922-10","volume":"54","author":"NC Gordon","year":"2010","unstructured":"Gordon, N. C., Png, K. & Wareham, D. W. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 54, 5316\u20135322 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2014164_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ijantimicag.2007.07.007","volume":"30","author":"MF Tripodi","year":"2007","unstructured":"Tripodi, M. F., Durante-Mangoni, E., Fortunato, R., Utili, R. & Zarrilli, R. Comparative activities of colistin, rifampicin, imipenem and sulbactam\/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int. J. Antimicrob. Agents 30, 537\u2013540 (2007).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFja2014164_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1128\/AAC.50.2.825-826.2006","volume":"50","author":"DW Wareham","year":"2006","unstructured":"Wareham, D. W. & Bean, D. C. In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50, 825\u2013826 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2014164_CR7","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2165\/11538110-000000000-00000","volume":"70","author":"A Subissi","year":"2010","unstructured":"Subissi, A., Monti, D., Togni, G. & Mailland, F. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 70, 2133\u20132152 (2010).","journal-title":"Drugs"},{"key":"BFja2014164_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1742-4690-6-90","volume":"6","author":"M Hoque","year":"2009","unstructured":"Hoque, M. et al. Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology 6, 90 (2009).","journal-title":"Retrovirology"},{"key":"BFja2014164_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjp.0706206","volume":"145","author":"SJ Lee","year":"2005","unstructured":"Lee, S. J. et al. Ciclopirox protects mitochondria from hydrogen peroxide toxicity. Br. J. Pharmacol. 145, 469\u2013476 (2005).","journal-title":"Br. J. Pharmacol."},{"key":"BFja2014164_CR10","doi-asserted-by":"publisher","first-page":"e27844","DOI":"10.1371\/journal.pone.0027844","volume":"6","author":"SH Ko","year":"2011","unstructured":"Ko, S. H. et al. Antimycotic ciclopirox olamine in the diabetic environment promotes angiogenesis and enhances wound healing. PLoS One 6, e27844 (2011).","journal-title":"PLoS One"},{"key":"BFja2014164_CR11","doi-asserted-by":"publisher","first-page":"e69646","DOI":"10.1371\/journal.pone.0069646","volume":"8","author":"KM Carlson-Banning","year":"2013","unstructured":"Carlson-Banning, K. M. et al. Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii Escherichia coli, and Klebsiella pneumoniae. PLoS ONE 8, e69646 (2013).","journal-title":"PLoS ONE"},{"key":"BFja2014164_CR12","doi-asserted-by":"publisher","first-page":"e36649","DOI":"10.1371\/journal.pone.0036649","volume":"7","author":"B Huttner","year":"2012","unstructured":"Huttner, B. et al. Drugs of last resort? The use of polymyxins and tigecycline at US veterans affairs medical centers, 2005\u20132010. PLoS One 7, e36649 (2012).","journal-title":"PLoS One"},{"key":"BFja2014164_CR13","unstructured":"Elipoulos, G. M. & Moellering, R. C. in Antibiotic in Laboratory Medicine 4th edn (ed. Lorian, V.) 330\u2013396 (William and Wilkins Baltimore, MD, 1996)."},{"key":"BFja2014164_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ja.2014.99","volume":"67","author":"X Dong","year":"2014","unstructured":"Dong, X. et al. In vitro activities of rifampicin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii. J. Antibiot. 67, 677\u2013680 (2014).","journal-title":"J. Antibiot."},{"key":"BFja2014164_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1128\/AAC.48.3.753-757.2004","volume":"48","author":"J Yoon","year":"2004","unstructured":"Yoon, J., Urban, C., Terzian, C., Mariano, N. & Rahal, J. J. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48, 753\u2013757 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2014164_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1476-0711-5-10","volume":"5","author":"DW Wareham","year":"2006","unstructured":"Wareham, D. W. & Bean, D. C. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob 5, 10 (2006).","journal-title":"Ann. Clin. Microbiol. Antimicrob"},{"key":"BFja2014164_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3201\/eid1805.111153","volume":"18","author":"DA Tadesse","year":"2012","unstructured":"Tadesse, D. A. et al. Antimicrobial drug resistance in Escherichia coli from humans and food animals, United States, 1950\u20132002. Emerg. Infect. Dis. 18, 741\u2013749 (2012).","journal-title":"Emerg. Infect. Dis."},{"key":"BFja2014164_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/jac\/dkq046","volume":"65","author":"B Zhai","year":"2010","unstructured":"Zhai, B. et al. Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J. Antimicrob. Chemother. 65, 931\u2013938 (2010).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja2014164_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ajh.23640","volume":"89","author":"MD Minden","year":"2014","unstructured":"Minden, M. D. et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. Am. J. Hematol. 89, 363\u2013368 (2014).","journal-title":"Am. J. Hematol."},{"key":"BFja2014164_CR20","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1128\/jb.176.13.4144-4156.1994","volume":"176","author":"G Stevenson","year":"1994","unstructured":"Stevenson, G. et al. Structure of the O antigen of Escherichia coli K-12 and the sequence of its rfb gene cluster. J. Bacteriol. 176, 4144\u20134156 (1994).","journal-title":"J. Bacteriol."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ja2014164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja2014164","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja2014164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:21:01Z","timestamp":1684430461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja2014164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,14]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["BFja2014164"],"URL":"https:\/\/doi.org\/10.1038\/ja.2014.164","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,14]]},"assertion":[{"value":"14 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}